|
A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research. While the vaccine works to a degree on its own, the tumor can still activate backup strategies for survival. But when combined with existing immune checkpoint inhibitors, the one-two punch proves highly effective, the researchers found.
|